Developer docs
API playgroundTry for free, no card

Search company profiles

IDBiologics

Full company profile

uuid00037vi

Namestring
IDBiologics
Legal namestring
IDBiologics, Inc.
Websiteurl
idbiologics.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

IDBiologics is a privately held clinical-stage biotechnology company founded in 2017 and headquartered in Nashville, Tennessee, that develops fully human monoclonal antibodies for the prevention and treatment of infectious diseases. The company was founded from the laboratory of Professor James Crowe at Vanderbilt University Medical Center, whose research underpins the company's proprietary fully human mAb platform for rapid discovery and optimization of broad, potent therapeutic antibodies with neutralizing activity against diverse viral targets.

IDBiologics' pipeline comprises six clinical lead candidate molecules, each with animal proof-of-concept: BK virus (BKV) antibodies for immunocompromised transplant patients; a two-mAb pan-influenza combination engineered for approximately six-month duration and ~90% neutralizing efficacy against influenza A and B including pre-pandemic strains; RSV-199, a single cross-neutralizing antibody for RSV and HMPV; IDB002 for Zika virus pre-exposure prophylaxis; a two-mAb Rift Valley fever virus (RVFV) therapy; and an EV-D68 program for pediatric respiratory enterovirus.

The company's business model centers on non-dilutive U.S. Government funding, with five USG grants totaling $38 million and a 2023 Department of Defense contract for RVFV antibody development through Phase 1. Revenue-generating mechanisms are limited to government contracts and grants at present, with future commercial product sales, licensing, and royalties as longer-term monetization pathways. Key customers are U.S. government biodefense agencies, with downstream commercial targets including healthcare providers serving immunocompromised and elderly patients and global public health organizations. Leadership includes Co-Founder and CEO Ken Kelley, Co-Founder and President Chuck Haines, Chief Business Officer Felix Karim, and Founder James Crowe.

Short descriptiontext

IDBiologics is a Nashville-based clinical-stage biotechnology company founded in 2017 that develops fully human monoclonal antibodies for preventing and treating infectious diseases, serving U.S. government biodefense agencies and targeting immunocompromised and elderly patient populations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNashville, United States
HQ citystring
Nashville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
monoclonal antibody therapeutics, infectious disease prevention, biodefense countermeasures, antibody drug development, viral neutralization research
Industry4 codes
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)
SECONDARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Scientific Research and Development Services5417
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Infectious Disease Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Government Contracts and Grants
TypeOthers
Description

IDBiologics pursues non-dilutive funding through U.S. government grants and contracts, including Department of Defense contracts for medical countermeasures development. The company has secured 5 USG grants totaling $38 million and a DOD contract for RVFV antibody development through Phase 1.

idbiologics.com
2Commercial Product Development
TypeLicensing Royalties
Description

Development of monoclonal antibody therapeutics for commercial markets targeting infectious diseases including BKV, pan-influenza, RSV/HMPV, and other viral threats. Public health programs funded by non-dilutive grants help de-risk formulation technologies for both public health and commercial mAb products.

idbiologics.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

IDBiologics discovers and develops fully human monoclonal antibodies (mAbs) for the prevention and treatment of serious infectious diseases. Leveraging a platform spun out of Professor James Crowe's laboratory at Vanderbilt University Medical Center, the company advances a pipeline of six clinical lead candidate molecules targeting BKV, pan-influenza (A+B), RSV/HMPV, Zika virus (ZIKV), Rift Valley fever virus (RVFV), and Enterovirus D68 (EV-D68). Programs span both commercial indications and global public health / biodefense applications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 90% neutralizing efficacy expected against pan-influenza (A+B) strains
+2 more records
Product overview1 text field

IDBiologics is developing a pipeline of human monoclonal antibodies (mAbs) for the prevention and treatment of serious infectious diseases. The company's portfolio includes six clinical lead candidate molecules targeting diverse pathogens: BKV (BK virus) for transplant patients, Pan-Influenza (A+B) combining two mAbs with six-month duration, RSV-199 for RSV/HMPV co-infection, IDB002 for Zika virus prophylaxis, RVFV (Rift Valley Fever virus) as a biothreat countermeasure, and EV-D68 for pediatric respiratory infection. The platform was founded from Professor James Crowe's laboratory at Vanderbilt University Medical Center and enables rapid discovery and optimization of broad, potent therapeutic mAbs with neutralizing activity.

Product and service6 records
1BKV (BK Virus) Program
CategoryInfectious Disease Therapeutics
Description

Panel of anti-BKV monoclonal antibodies including a lead and back-up clinical candidate developed as prevention of BKV viremia/DNAemia and BKV-associated nephropathy (BKVAN) in immunocompromised patients, particularly kidney transplant recipients.

2Pan-Influenza (A+B) Program
CategoryInfectious Disease Therapeutics
Description

Combination of two ultra-potent human monoclonal antibodies engineered for approximately six-month duration of action, designed to achieve about 90% neutralizing efficacy against pan-influenza A and B strains, including pre-pandemic H5N1 and H7N9 strains.

3RSV-199 (RSV/HMPV Program)
CategoryInfectious Disease Therapeutics
Description

Single human monoclonal antibody, RSV-199, that cross-neutralizes both RSV A and B strains and HMPV, offering enhanced protection demonstrated in cotton rat models supporting broad neutralization and therapeutic potential.

4IDB002 (Zika Virus Program)
CategoryInfectious Disease Therapeutics
Description

Ultra-potent neutralizing monoclonal antibody being developed as an off-the-shelf pre-exposure prophylaxis (PrEP) against Zika virus infection, addressing the risk of Congenital Zika Syndrome in developing fetuses.

5RVFV (Rift Valley Fever Virus) Program
CategoryBiodefense / Medical Countermeasures
Description

Two human monoclonal antibodies that directly inhibit RVFV replication without binding to the same critical residues, engineered with extended half-life for combination therapeutic and preventive use against this emerging arbovirus with pandemic potential. Developed with U.S. Department of Defense funding.

6EV-D68 (Enterovirus D68) Program
CategoryInfectious Disease Therapeutics
Description

Monoclonal antibody program targeting Enterovirus D68, a respiratory enterovirus with no available vaccines or treatments, primarily affecting children.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-05-12
Description

IDBiologics entered into a contract with the U.S. Department of Defense to accelerate development of human mAbs as medical countermeasures against targeted infectious disease threats. The first project is a two-antibody medicine to prevent RVFV infection, with the initial phase funding preclinical development through completion of Phase 1 human clinical studies. The contract was awarded by the Joint Project Lead for CBRND Enabling Biotechnologies within the DOD's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense.

2Vanderbilt University Medical Center (VUMC)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Vanderbilt University licensed the rights to RVFV antibodies to IDBiologics. Professor James Crowe and his laboratory at VUMC lead preclinical assessment of neutralizing activity, while IDBiologics leads preclinical safety and toxicology studies, manufacturing process development, production for clinical trials, and execution of Phase 1 clinical trial. The company was founded from Professor Crowe's laboratory.

idbiologics.com
3Global Pandemic Prevention and Biodefense Center (GPPBC)
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

The Global Pandemic Prevention and Biodefense Center is assisting with planning for late-stage development, stockpiling, and long-term use of the RVFV antibody medicine, although those activities are outside the scope of the DOD contract.

idbiologics.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage immunology company developing monoclonal antibodies for serious infectious diseases including influenza (VIR-2482) and COVID-19 (sotrovimab). Highly comparable to IDBiologics in therapeutic modality, infectious-disease focus, and target overlap on pan-influenza and respiratory pathogens.

TypeBroad incumbent
Description

Large established biotech with a market-leading antibody platform (VelocImmune) and multiple approved/infectious-disease mAbs including REGN-COV2 for COVID-19 and Ebola antibody treatments. Represents the gold-standard incumbent that IDBiologics' technology platform is positioned alongside in infectious-disease mAbs.

3IGM Biosciences
TypeDirect peer
Description

Clinical-stage biotech developing engineered IgM and IgG antibodies for infectious diseases and immune-mediated conditions, with active programs in COVID-19 and other viral targets. Comparable antibody-platform biotech at similar clinical stage targeting overlapping infectious-disease indications.

TypeBroad incumbent
Description

Global biopharmaceutical company with significant infectious-disease mAb franchise including Evusheld (tixagevimab/cilgavimab) for COVID-19 pre-exposure prophylaxis. Comparable as a manufacturer of antibody-based prophylaxis for vulnerable populations and a competitor for biodefense and pandemic preparedness stockpiling programs.

TypeDirect peer
Description

Clinical-stage biotech specializing in monoclonal antibody countermeasures for high-consequence infectious diseases and biothreats, including FDA-approved Ebanga (ansuvimab) for Ebola. Highly comparable mission and biodefense focus to IDBiologics with similar government contract-based funding model.

TypeBroad incumbent
Description

Large pharmaceutical company that developed bebtelovimab and other infectious-disease mAbs targeting COVID-19 and other pathogens. Comparable as a vertically integrated mAb developer pursuing infectious-disease indications, including seasonal flu and biodefense-adjacent opportunities.

TypeEmerging player
Description

Clinical-stage biotech developing polyclonal and engineered human antibodies for infectious diseases including influenza and emerging viral threats, with DARPA and BARDA funding history. Partially comparable platform with adjacent technology targeting similar biodefense indications.

TypeEmerging player
Description

Clinical-stage mRNA and infectious-disease biotech with active programs in influenza, COVID-19, and other viral pathogens. Indirect comparator pursuing infectious-disease prophylaxis through a different modality (mRNA) targeting comparable seasonal and pandemic preparedness indications.

TypeOthers
Description

Industry-leading antibody discovery platform company enabling pharma partners to discover human mAbs. Comparable as a fully human antibody discovery engine; functions as an enabling platform rather than a downstream competitor, but represents an alternative approach to mAb generation that biotech sponsors may choose instead of internal platforms like IDBiologics'.

10Humanigen (formerly)
TypeEmerging player
Description

Small clinical-stage biotech developing monoclonal antibodies for infectious and inflammatory diseases (lenzilumab for COVID-19). Comparable as a small-cap mAb developer pursuing infectious-disease indications through a similar government- and partner-funded clinical-development model, though Humanigen's pipeline struggled commercially.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

IDBiologics

Infectious Disease Therapeuticsidbiologics.com

IDBiologics is a Nashville-based clinical-stage biotechnology company founded in 2017 that develops fully human monoclonal antibodies for preventing and treating infectious diseases, serving U.S. government biodefense agencies and targeting immunocompromised and elderly patient populations.

What IDBiologics does

IDBiologics is a privately held clinical-stage biotechnology company founded in 2017 and headquartered in Nashville, Tennessee, that develops fully human monoclonal antibodies for the prevention and treatment of infectious diseases. The company was founded from the laboratory of Professor James Crowe at Vanderbilt University Medical Center, whose research underpins the company's proprietary fully human mAb platform for rapid discovery and optimization of broad, potent therapeutic antibodies with neutralizing activity against diverse viral targets.

IDBiologics' pipeline comprises six clinical lead candidate molecules, each with animal proof-of-concept: BK virus (BKV) antibodies for immunocompromised transplant patients; a two-mAb pan-influenza combination engineered for approximately six-month duration and ~90% neutralizing efficacy against influenza A and B including pre-pandemic strains; RSV-199, a single cross-neutralizing antibody for RSV and HMPV; IDB002 for Zika virus pre-exposure prophylaxis; a two-mAb Rift Valley fever virus (RVFV) therapy; and an EV-D68 program for pediatric respiratory enterovirus.

The company's business model centers on non-dilutive U.S. Government funding, with five USG grants totaling $38 million and a 2023 Department of Defense contract for RVFV antibody development through Phase 1. Revenue-generating mechanisms are limited to government contracts and grants at present, with future commercial product sales, licensing, and royalties as longer-term monetization pathways. Key customers are U.S. government biodefense agencies, with downstream commercial targets including healthcare providers serving immunocompromised and elderly patients and global public health organizations. Leadership includes Co-Founder and CEO Ken Kelley, Co-Founder and President Chuck Haines, Chief Business Officer Felix Karim, and Founder James Crowe.

IDBiologics firmographics

Firmographics
Name
IDBiologics
Legal name
IDBiologics, Inc.
Website
https://idbiologics.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
IDBiologics is a Nashville-based clinical-stage biotechnology company founded in 2017 that develops fully human monoclonal antibodies for preventing and treating infectious diseases, serving U.S. government biodefense agencies and targeting immunocompromised and elderly patient populations.
Ownership category
akta.pro rank

IDBiologics industry classification

Industry
Product category
Infectious Disease Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAA
Monoclonal Antibody Therapeutics (mAbs)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIACAM
Infectious Disease Specialty Pharmaceuticals (Non-vaccine)
SECONDARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Monoclonal antibody therapeutics
  • Infectious disease prevention
  • Biodefense countermeasures
  • Antibody drug development
  • Viral neutralization research

Where IDBiologics is headquartered

Location

Headquarters

HQ city
Nashville
HQ country
United States
HQ region
North America

Offices2 records

Markets served

IDBiologics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Government Contracts and Grants: IDBiologics pursues non-dilutive funding through U.S. government grants and contracts, including Department of Defense contracts for medical countermeasures development. The company has secured 5 USG grants totaling $38 million and a DOD contract for RVFV antibody development through Phase 1.
  2. Commercial Product Development: Development of monoclonal antibody therapeutics for commercial markets targeting infectious diseases including BKV, pan-influenza, RSV/HMPV, and other viral threats. Public health programs funded by non-dilutive grants help de-risk formulation technologies for both public health and commercial mAb products.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

IDBiologics product offering

Product offering

Core offering

IDBiologics discovers and develops fully human monoclonal antibodies (mAbs) for the prevention and treatment of serious infectious diseases. Leveraging a platform spun out of Professor James Crowe's laboratory at Vanderbilt University Medical Center, the company advances a pipeline of six clinical lead candidate molecules targeting BKV, pan-influenza (A+B), RSV/HMPV, Zika virus (ZIKV), Rift Valley fever virus (RVFV), and Enterovirus D68 (EV-D68). Programs span both commercial indications and global public health / biodefense applications.

Product overview

IDBiologics is developing a pipeline of human monoclonal antibodies (mAbs) for the prevention and treatment of serious infectious diseases. The company's portfolio includes six clinical lead candidate molecules targeting diverse pathogens: BKV (BK virus) for transplant patients, Pan-Influenza (A+B) combining two mAbs with six-month duration, RSV-199 for RSV/HMPV co-infection, IDB002 for Zika virus prophylaxis, RVFV (Rift Valley Fever virus) as a biothreat countermeasure, and EV-D68 for pediatric respiratory infection. The platform was founded from Professor James Crowe's laboratory at Vanderbilt University Medical Center and enables rapid discovery and optimization of broad, potent therapeutic mAbs with neutralizing activity.

Differentiator

Problem solved

Functional benefit

Products and services

  • BKV (BK Virus) Program Panel of anti-BKV monoclonal antibodies including a lead and back-up clinical candidate developed as prevention of BKV viremia/DNAemia and BKV-associated nephropathy (BKVAN) in immunocompromised patients, particularly kidney transplant recipients.
  • Pan-Influenza (A+B) Program Combination of two ultra-potent human monoclonal antibodies engineered for approximately six-month duration of action, designed to achieve about 90% neutralizing efficacy against pan-influenza A and B strains, including pre-pandemic H5N1 and H7N9 strains.
  • RSV-199 (RSV/HMPV Program) Single human monoclonal antibody, RSV-199, that cross-neutralizes both RSV A and B strains and HMPV, offering enhanced protection demonstrated in cotton rat models supporting broad neutralization and therapeutic potential.
  • IDB002 (Zika Virus Program) Ultra-potent neutralizing monoclonal antibody being developed as an off-the-shelf pre-exposure prophylaxis (PrEP) against Zika virus infection, addressing the risk of Congenital Zika Syndrome in developing fetuses.
  • RVFV (Rift Valley Fever Virus) Program Two human monoclonal antibodies that directly inhibit RVFV replication without binding to the same critical residues, engineered with extended half-life for combination therapeutic and preventive use against this emerging arbovirus with pandemic potential. Developed with U.S. Department of Defense funding.
  • EV-D68 (Enterovirus D68) Program Monoclonal antibody program targeting Enterovirus D68, a respiratory enterovirus with no available vaccines or treatments, primarily affecting children.

Quantifiable outcome

  • 90% neutralizing efficacy expected against pan-influenza (A+B) strains
  • +2 more outcomes

Companies that use IDBiologics

Customer profile

Segments3 records

Ideal customer profiles3 records

IDBiologics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

IDBiologics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and supporting.

  • United States Department of Defense (DOD)coreStrategic or Co-development Partner · 12 May 2023IDBiologics entered into a contract with the U.S. Department of Defense to accelerate development of human mAbs as medical countermeasures against targeted infectious disease threats. The first project is a two-antibody medicine to prevent RVFV infection, with the initial phase funding preclinical development through completion of Phase 1 human clinical studies. The contract was awarded by the Joint Project Lead for CBRND Enabling Biotechnologies within the DOD's Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense.
  • Vanderbilt University Medical Center (VUMC)coreStrategic or Co-development PartnerVanderbilt University licensed the rights to RVFV antibodies to IDBiologics. Professor James Crowe and his laboratory at VUMC lead preclinical assessment of neutralizing activity, while IDBiologics leads preclinical safety and toxicology studies, manufacturing process development, production for clinical trials, and execution of Phase 1 clinical trial. The company was founded from Professor Crowe's laboratory.
  • Global Pandemic Prevention and Biodefense Center (GPPBC)supportingStrategic or Co-development PartnerThe Global Pandemic Prevention and Biodefense Center is assisting with planning for late-stage development, stockpiling, and long-term use of the RVFV antibody medicine, although those activities are outside the scope of the DOD contract.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

IDBiologics competitors and assessment

Company assessment

Direct peers

  • Vir Biotechnology: Clinical-stage immunology company developing monoclonal antibodies for serious infectious diseases including influenza (VIR-2482) and COVID-19 (sotrovimab). Highly comparable to IDBiologics in therapeutic modality, infectious-disease focus, and target overlap on pan-influenza and respiratory pathogens.
  • IGM Biosciences: Clinical-stage biotech developing engineered IgM and IgG antibodies for infectious diseases and immune-mediated conditions, with active programs in COVID-19 and other viral targets. Comparable antibody-platform biotech at similar clinical stage targeting overlapping infectious-disease indications.
  • Mapp Biopharmaceutical: Clinical-stage biotech specializing in monoclonal antibody countermeasures for high-consequence infectious diseases and biothreats, including FDA-approved Ebanga (ansuvimab) for Ebola. Highly comparable mission and biodefense focus to IDBiologics with similar government contract-based funding model.

Broad incumbents

  • Regeneron Pharmaceuticals: Large established biotech with a market-leading antibody platform (VelocImmune) and multiple approved/infectious-disease mAbs including REGN-COV2 for COVID-19 and Ebola antibody treatments. Represents the gold-standard incumbent that IDBiologics' technology platform is positioned alongside in infectious-disease mAbs.
  • AstraZeneca: Global biopharmaceutical company with significant infectious-disease mAb franchise including Evusheld (tixagevimab/cilgavimab) for COVID-19 pre-exposure prophylaxis. Comparable as a manufacturer of antibody-based prophylaxis for vulnerable populations and a competitor for biodefense and pandemic preparedness stockpiling programs.
  • Eli Lilly: Large pharmaceutical company that developed bebtelovimab and other infectious-disease mAbs targeting COVID-19 and other pathogens. Comparable as a vertically integrated mAb developer pursuing infectious-disease indications, including seasonal flu and biodefense-adjacent opportunities.

Emerging players

  • SAB Biotherapeutics: Clinical-stage biotech developing polyclonal and engineered human antibodies for infectious diseases including influenza and emerging viral threats, with DARPA and BARDA funding history. Partially comparable platform with adjacent technology targeting similar biodefense indications.
  • Arcturus Therapeutics: Clinical-stage mRNA and infectious-disease biotech with active programs in influenza, COVID-19, and other viral pathogens. Indirect comparator pursuing infectious-disease prophylaxis through a different modality (mRNA) targeting comparable seasonal and pandemic preparedness indications.
  • Humanigen (formerly): Small clinical-stage biotech developing monoclonal antibodies for infectious and inflammatory diseases (lenzilumab for COVID-19). Comparable as a small-cap mAb developer pursuing infectious-disease indications through a similar government- and partner-funded clinical-development model, though Humanigen's pipeline struggled commercially.

Others

  • Adimab: Industry-leading antibody discovery platform company enabling pharma partners to discover human mAbs. Comparable as a fully human antibody discovery engine; functions as an enabling platform rather than a downstream competitor, but represents an alternative approach to mAb generation that biotech sponsors may choose instead of internal platforms like IDBiologics'.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key highlights7 records

Customer concentration

IDBiologics social profiles

Digital presence

IDBiologics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

IDBiologics leadership team

Management profile

Number of profiles

Profiles4 records

IDBiologics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

IDBiologics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IDBiologics

What does IDBiologics do?

IDBiologics discovers and develops fully human monoclonal antibodies (mAbs) for the prevention and treatment of serious infectious diseases. Leveraging a platform spun out of Professor James Crowe's laboratory at Vanderbilt University Medical Center, the company advances a pipeline of six clinical lead candidate molecules targeting BKV, pan-influenza (A+B), RSV/HMPV, Zika virus (ZIKV), Rift Valley fever virus (RVFV), and Enterovirus D68 (EV-D68). Programs span both commercial indications and global public health / biodefense applications.

Is IDBiologics a public or private company?

IDBiologics is a private company. It is classified as venture growth investor backed and is currently operating.

When was IDBiologics founded?

IDBiologics was founded in 2017. It employs 1 to 10 people.

Where is IDBiologics based?

IDBiologics is headquartered in Nashville, United States, in the North America region.

How does IDBiologics make money?

Two revenue lines are on record. Government Contracts and Grants are the primary driver. The others are commercial Product Development.

Who are IDBiologics's main competitors?

Direct peers on record are Vir Biotechnology, IGM Biosciences and Mapp Biopharmaceutical. Broad incumbents are Regeneron Pharmaceuticals, AstraZeneca and Eli Lilly. Emerging players are SAB Biotherapeutics, Arcturus Therapeutics and Humanigen (formerly). Adimab is listed as an others.

Does IDBiologics have an API?

No public API is recorded for IDBiologics.

What industry is IDBiologics in?

IDBiologics's product category is Infectious Disease Therapeutics. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs), with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Vanderbilt UniversityDiscovery Vanderbilt invests in three faculty-initiated startups: HeroWear, IDBiologics and VirtuosoDiscovery Vanderbilt approved seed and Series A investments in three faculty-initiated startups: HeroWear, IDBiologics, and Virtuoso Surgical. HeroWear received $250,000, while IDBiologics and Virtuoso each received $500,000. The committee plans continued support for Vanderbilt-initiated startups.Ow.ly Link ShortenerDiscovery Vanderbilt invests in three faculty-initiated startups: HeroWear, IDBiologics and VirtuosoVanderbilt's chancellor and provost offices approved Discovery Vanderbilt seed investments in three faculty-initiated startups: HeroWear, IDBiologics and Virtuoso Surgical. HeroWear received $250,000, while IDBiologics and Virtuoso each received $500,000 in seed and Series A funding. The committee, led by Brett Sweet, plans continued support of Vanderbilt and VUMC ventures.MedicalxpressAntibody research shows promise in fight against COVID-19Researchers at Vanderbilt University Medical Center identified monoclonal antibodies from two early COVID-19 patients that reduce viral burden in mice and protect rhesus macaques. The antibodies are promising candidates for prevention or treatment, with AstraZeneca and IDBiologics licensing them for clinical trials this summer.GlobeNewswireBatavia Biosciences to deploy Horizon Discovery’s CHO cell technology to develop anti-Zika biotherapeutic with Vanderbilt University Medical Center and IDBiologicsBatavia Biosciences signed a license agreement with Horizon Discovery to use its GS knockout CHO K1 cell line for developing a Zika virus neutralizing antibody. The antibody, discovered by Vanderbilt University Medical Center researchers, was reported to markedly reduce infection in a mouse model. The collaboration aims to advance the therapy toward clinical development.CttcventurestudioDiscovery Vanderbilt invests in three faculty-initiated startups: HeroWear, IDBiologics and VirtuosoVanderbilt University's chancellor and provost offices approved Discovery Vanderbilt seed investments in three faculty-initiated startups: HeroWear, IDBiologics and Virtuoso Surgical Inc. HeroWear received $250,000, while IDBiologics and Virtuoso each received $500,000 in seed and Series A funding. The committee, led by Brett Sweet, plans continued support of Vanderbilt and VUMC faculty, students, alumni and Wond'ry participants.